Table 4.
C5-9b and MHC I deposition in anti-HMGCR myopathy and DM.
| C5-9b deposition | MHC I | ||
|---|---|---|---|
| HMGCR Patient | Endothelial | Sacrolemmal | |
| 1 | Y | Y | Y |
| 2 | N | N | N |
| 3 | N | Y | Y |
| 4 | N | Y | Y |
| 5 | N | Y | Y |
| 6 | Y | Y | Y |
| 7 | N | Y | Y |
| 8 | N | Y | Y |
| 10 | N | N | Y |
| 11 | Y | Y | Y |
| 12 | N | Y | Y |
| 13 | N | N/A | N |
| 14 | Y | Y | Y |
| 15 | Y | Y | Y |
| 17 | N | N/A | Y |
| 18 | Y | Y | Y |
| DM Patient | |||
| 1 | Y | N | Y |
| 2 | N | N | Y |
| 3 | Y | N | Y |
| 4 | N | Y | Y |
| 5 | Y | N | Y |
| 6 | N/A | N/A | N/A |
| 7 | Y | N | Y |
“Y” = at least 1 endomysial capillary or myofiber sarcolemma staining positive for C5-9b. “N” = absence of such staining in the entire biopsy sample. “N/A” = staining technically inadequate for interpretation.